Risk factors
HeartSciences (HSCS) risk factors
Item 1A of every HeartSciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors80 risks13 new12 dropped11 reworded
AI-ECG performance, FDA and EU AI regulation now dominate product commercialization risks.
Filed Jul 23, 2026 - FY2025 10-K risk factors79 risks
HeartSciences is a development-stage medical device company heavily dependent on FDA approval and commercialization of its MyoVista wavECG and cloud platform. The company faces severe liquidity issues, Nasdaq delisting risks due to low stock price and stockholders equity, and internal control weaknesses. Operations rely on third-party suppliers, cloud providers, and clinical trial partners without current third-party payor reimbursement.
Filed Jul 24, 2025